Comparison of standard triple therapy, sequential therapy and moxifloxacin‐based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates. Issue 9 (September 2014)

• Record Type: Journal Article
• Authors: Rakici, Halil; Akdoğan, Remzi Adnan; Bedir, Recep; Copur, Aysegul; Yilmaz, Arif
• Is Part Of: Journal of digestive diseases. Volume 15:Issue 9(2014:Sep.)
• Page Start: 508
• Page End: 513
• Publication Date: 2014-09
• Subjects: Digestive organs -- Diseases -- Periodicals; Gastroenterology -- Periodicals; 616.3
• DOI: 10.1111/1751-2980.12171
• Languages: English
• ISSNs: 1751-2972

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cdd12171-sec-0001" sec-type="section"> <title>Objective</title> <p>To compare the patients' compliance with and the efficacy of existing treatments for <italic>Helicobacter pylori</italic> eradication, including moxifloxacin‐based triple therapy, sequential treatment and the standard treatment.</p> </sec> <sec id="cdd12171-sec-0002" sec-type="section"> <title>Methods</title> <p>Patients with <italic>H. pylori</italic> infection were randomly assigned to three therapy groups. The triple therapy (MML) group was given moxifloxacin 400 mg/day, metronidazole 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for 10 days. The sequential treatment (AL‐CML) group was administrated amoxicillin 1 g b.i.d. and lansoprazole 30 mg b.i.d. for the first 5 days, followed by clarithromycin 500 mg b.i.d., metronidazole 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for the second 5 days. The standard treatment (CAL) group received amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for 14 days. The eradication rates were evaluated by per‐protocol (PP) analysis and intention‐to‐treat (ITT) analysis.</p> </sec> <sec id="cdd12171-sec-0003" sec-type="section"> <title>Results</title> <p>The eradication rates were 87.1, 85.9 and 85.2% by PP analysis and 87.1, 84.9 and 84.2% by ITT analysis in the MML, AL‐CML and CAL group, respectively, and patients' compliance rates were 98.2, 96.5 and 97.1%, respectively. There were no significant differences in treatment efficacy and compliance rates in the MML, AL‐CML and CAL groups (<italic>P</italic> > 0.05).</p> </sec> <sec id="cdd12171-sec-0004" sec-type="section"> <title>Conclusions</title> <p>The present study revealed that standard triple therapy, sequential therapy and moxifloxacin‐based triple therapy are all effective treatment regimens in terms of <italic>H. pylori</italic> eradication rates and compliance with therapy in Turkey.</p> </sec> </abstract>